Tamoxifen is being evaluated in clinical trials as a preventive agent in women at high risk for breast cancer. This new, potentially long-term therapeutic role has generated some concerns regarding safety, based on the results of
James A. Swenberg, DMV, PhD
Advertisement
Articles by James A. Swenberg, DMV, PhD
Advertisement
Latest Updated Articles
- Clinical Relevance of Laboratory and Animal Data on Tamoxifen
February 1st 1997
Advertisement
Advertisement
Trending on CancerNetwork
1
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis
4
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
5